Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

1.

Assessment of circulating serum DNA integrity in colorectal cancer patients.

Yörüker EE, Özgür E, Keskin M, Dalay N, Holdenrieder S, Gezer U.

Anticancer Res. 2015 Apr;35(4):2435-40.

PMID:
25862911
2.

Androgen Stimulation of PCA3 and miR-141 and Their Release from Prostate Cancer Cells.

Gezer U, Tiryakioglu D, Bilgin E, Dalay N, Holdenrieder S.

Cell J. 2015 Winter;16(4):488-93. Epub 2015 Jan 13.

3.

Analysis of tissue and serum microRNA expression in patients with upper urinary tract urothelial cancer.

Kriebel S, Schmidt D, Holdenrieder S, Goltz D, Kristiansen G, Moritz R, Fisang C, Müller SC, Ellinger J.

PLoS One. 2015 Jan 28;10(1):e0117284. doi: 10.1371/journal.pone.0117284. eCollection 2015.

4.

Methodical and pre-analytical characteristics of a multiplex cancer biomarker immunoassay.

Hermann N, Dreßen K, Schildberg FA, Jakobs C, Holdenrieder S.

World J Methodol. 2014 Dec 26;4(4):219-31. doi: 10.5662/wjm.v4.i4.219. eCollection 2014 Dec 26.

5.

Assessing novel prognostic serum biomarkers in advanced pancreatic cancer: the role of CYFRA 21-1, serum amyloid A, haptoglobin, and 25-OH vitamin D3.

Haas M, Kern C, Kruger S, Michl M, Modest DP, Giessen C, Schulz C, von Einem JC, Ormanns S, Laubender RP, Holdenrieder S, Heinemann V, Boeck S.

Tumour Biol. 2015 Apr;36(4):2631-40. doi: 10.1007/s13277-014-2885-x. Epub 2014 Dec 4.

PMID:
25472579
6.

Characterizing the genetic basis of innate immune response in TLR4-activated human monocytes.

Kim S, Becker J, Bechheim M, Kaiser V, Noursadeghi M, Fricker N, Beier E, Klaschik S, Boor P, Hess T, Hofmann A, Holdenrieder S, Wendland JR, Fröhlich H, Hartmann G, Nöthen MM, Müller-Myhsok B, Pütz B, Hornung V, Schumacher J.

Nat Commun. 2014 Oct 20;5:5236. doi: 10.1038/ncomms6236.

PMID:
25327457
7.

[Detection of cell-free lncRNA in serum of cancer patients.]

Kohls K, Schmidt D, Holdenrieder S, Müller SC, Ellinger J.

Urologe A. 2014 Oct 15. [Epub ahead of print] German.

PMID:
25312755
8.

Multicenter evaluation of a new progastrin-releasing peptide (ProGRP) immunoassay across Europe and China.

Korse CM, Holdenrieder S, Zhi XY, Zhang X, Qiu L, Geistanger A, Lisy MR, Wehnl B, van den Broek D, Escudero JM, Standop J, Hu M, Molina R.

Clin Chim Acta. 2015 Jan 1;438:388-95. doi: 10.1016/j.cca.2014.09.015. Epub 2014 Sep 28.

9.

Serum autoantibody measurement for the detection of hepatocellular carcinoma.

Middleton CH, Irving W, Robertson JF, Murray A, Parsy-Kowalska CB, Macdonald IK, McElveen J, Allen J, Healey GF, Thomson BJ, Ryder SJ, Holdenrieder S, Chapman CJ.

PLoS One. 2014 Aug 5;9(8):e103867. doi: 10.1371/journal.pone.0103867. eCollection 2014.

10.

Circulating serum miRNA (miR-367-3p, miR-371a-3p, miR-372-3p and miR-373-3p) as biomarkers in patients with testicular germ cell cancer.

Syring I, Bartels J, Holdenrieder S, Kristiansen G, Müller SC, Ellinger J.

J Urol. 2015 Jan;193(1):331-7. doi: 10.1016/j.juro.2014.07.010. Epub 2014 Jul 18.

PMID:
25046619
11.

Increased DNA integrity in colorectal cancer.

Leszinski G, Lehner J, Gezer U, Holdenrieder S.

In Vivo. 2014 May-Jun;28(3):299-303.

PMID:
24815830
12.

Post-translational histone modifications in circulating nucleosomes as new biomarkers in colorectal cancer.

Gezer U, Holdenrieder S.

In Vivo. 2014 May-Jun;28(3):287-92. Review.

PMID:
24815828
13.

Novel serum nucleosomics biomarkers for the detection of colorectal cancer.

Holdenrieder S, Dharuman Y, Standop J, Trimpop N, Herzog M, Hettwer K, Simon K, Uhlig S, Micallef J.

Anticancer Res. 2014 May;34(5):2357-62.

PMID:
24778043
14.

miR-141 and miR-375 induction and release are different from PSA mRNA and PCA3 upon androgen stimulation of LNCaP cells.

Tiryakioglu D, Bilgin E, Holdenrieder S, Dalay N, Gezer U.

Biomed Rep. 2013 Sep;1(5):802-806. Epub 2013 Jul 15.

15.

Serum microRNAs as biomarkers in patients undergoing prostate biopsy: results from a prospective multi-center study.

Westermann AM, Schmidt D, Holdenrieder S, Moritz R, Semjonow A, Schmidt M, Kristiansen G, Müller SC, Ellinger J.

Anticancer Res. 2014 Feb;34(2):665-9.

PMID:
24510997
16.

Soluble intracellular adhesion molecule, M30 and M65 as serum markers of disease activity and prognosis in cholestatic liver diseases.

Denk G, Omary AJ, Reiter FP, Hohenester S, Wimmer R, Holdenrieder S, Rust C.

Hepatol Res. 2014 Dec;44(13):1286-98. doi: 10.1111/hepr.12304. Epub 2014 Feb 28.

PMID:
24451045
17.

Diagnostic relevance of plasma DNA and DNA integrity for breast cancer.

Stötzer OJ, Lehner J, Fersching-Gierlich D, Nagel D, Holdenrieder S.

Tumour Biol. 2014 Feb;35(2):1183-91. doi: 10.1007/s13277-013-1158-4. Epub 2013 Sep 10.

PMID:
24018822
18.

Circulating plasma DNA and DNA integrity in breast cancer patients undergoing neoadjuvant chemotherapy.

Lehner J, Stötzer OJ, Fersching D, Nagel D, Holdenrieder S.

Clin Chim Acta. 2013 Oct 21;425:206-11. doi: 10.1016/j.cca.2013.07.027. Epub 2013 Aug 2.

PMID:
23916787
19.

Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy.

Wittwer C, Boeck S, Heinemann V, Haas M, Stieber P, Nagel D, Holdenrieder S.

Int J Cancer. 2013 Dec 1;133(11):2619-30. doi: 10.1002/ijc.28294. Epub 2013 Aug 9.

PMID:
23729200
20.

Prediction of response to neoadjuvant chemotherapy in breast cancer patients by circulating apoptotic biomarkers nucleosomes, DNAse, cytokeratin-18 fragments and survivin.

Stoetzer OJ, Fersching DM, Salat C, Steinkohl O, Gabka CJ, Hamann U, Braun M, Feller AM, Heinemann V, Siegele B, Nagel D, Holdenrieder S.

Cancer Lett. 2013 Aug 9;336(1):140-8. doi: 10.1016/j.canlet.2013.04.013. Epub 2013 Apr 21.

PMID:
23612068
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk